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Introduction:Atheroembolization during renal artery angioplasty and stenting (RA-PTAS) has been postulated as a cause
for the inferior renal function results observed when compared with those with surgical revascularization. To further
characterize procedure-associated atheroembolism, we analyzed recovered atheroembolic debris and clinical data from
patients undergoing RA-PTAS with distal embolic protection (DEP).
Methods:RA-PTAS procedures were performedwithDEP using a commercially available temporary balloon occlusion and
aspiration catheter system between July 2005 and December 2006. Following RA-PTAS but prior to deflation of the
distal occlusion balloon, the static column of blood proximal to the balloon was aspirated and submitted for embolic
particle analysis. Angiograms, demographics, and laboratory data were reviewed. Glomerular filtration rate (eGFR) was
estimated before RA-PTAS and at 4 to 8 weeks postintervention using the abbreviated Modification of Diet in Renal
Disease formula. Associations between clinical factors, captured particle counts, and changes in renal function were
examined using univariate techniques and multiple linear regression.
Results: Twenty-eight RA-PTAS procedures were performed with DEP. Mean total number of embolic particles counted
per procedure was 2033  1553 for particles 20-60 m and 265  132 for particles >60 m. Significant positive
associations with quantity of captured particles 20 to 60 m were observed for African American race (P  .002),
predilation (P  .005), and stent diameter (P < .001); a significant negative association was observed for preoperative
aspirin use (P.016). Quantity of captured particles>60 mwas positively associated with ratio of stent to renal artery
diameter (P.009). Change in eGFR was positively associated with preoperative aspirin use (P .006) and preoperative
eGFR (P < .001), while a negative association was observed for captured particle counts >60 m (P  .015).
Conclusion: These results demonstrate the liberation of thousands of atheroembolic particles during RA-PTAS. Clinical,
anatomic, and device-related factors may be predictive of procedural embolization, and increasing captured particle
counts >60 m were associated with inferior renal function results. Further investigation is warranted to establish
relationships between atheroembolism, end organ functional impairment, and clinical responses. ( J Vasc Surg 2007;46:
55-61.)Atherosclerotic renovascular disease (RVD) is increas-
ingly recognized as a cause of severe secondary hyperten-
sion, renal insufficiency, and end-stage renal disease
through reductions in renal blood flow. RVD represents an
important public health problem as all of these associated
conditions have been demonstrated to increase cardiovas-
cular and all-cause mortality.1-5 Percutaneous transluminal
angioplasty and/or stenting of the renal artery (RA-PTAS)
and open surgical revascularization can be used to restore
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doi:10.1016/j.jvs.2007.03.039perfusion to affected kidneys. RA-PTAS has become the
more frequently employed treatment method in most cen-
ters and has demonstrated beneficial effects with regard to
improving control of renovascular hypertension in selected
patients.6-10 Reported results have been less favorable, how-
ever, in terms of improving associated renal insufficiency,6-10
which is the major determinant of subsequent cardiovascu-
lar morbidity and mortality as well as dialysis depen-
dence.11-13
Procedure-related atheroembolization has been postu-
lated as a cause for the disparate results observed between
surgical renal revascularization and RA-PTAS.14-16 This
hypothesis is supported by ex-vivo data 16 as well as obser-
vational data detailing results exceeding those of historical
controls with the use of commercially available distal em-
bolic protection (DEP) devices during RA-PTAS.14,17-20
To date, only limited in-vivo data exist regarding the debris
liberated during RA-PTAS. This report details recent ana-
lytic work investigating the characteristics of and factors
associated with atheroembolic debris collected during the
conduct of RA-PTAS using DEP.
METHODS
Patient population. This investigation was con-
ducted with approval from the Wake Forest University
55
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procedures were performed between July 2005 and De-
cember 2006 in patients with hemodynamically significant
atherosclerotic RVD (60% diameter-reducing stenosis by
renal duplex ultrasonography) and severe, difficult to con-
trol hypertension with or without associated renal insuffi-
ciency.
Materials reviewed. All outpatient clinic, hospital,
and endovascular operating suite records were reviewed.
Collected data included patient demographics, anthropo-
metrics, medical comorbidities, medications, laboratory re-
sults, procedure-specific data, and complications related to
RA-PTAS. Percent renal artery stenosis was calculated us-
ing a method congruent with that described in the Asymp-
tomatic Carotid Atherosclerosis Study.21 Distal renal artery
aspirates were collected at the time of RA-PTAS following
angioplasty stent placement, but prior to deflation of the
distal occlusion balloon, and analyzed at the University of
California at San Francisco as described below. All data
were maintained in a de-identified electronic database.
Operative management. All RA-PTAS were per-
formed in an endovascular operating suite at Wake Forest
University Baptist Medical Center. Patients were admitted
on the day before RA-PTAS to a 23-hour day hospital for
intravenous hydration and oral administration of 600 mg
N-acetylcysteine every 12 hours. Patients with severe renal
insufficiency (estimated glomerular filtration rate [eGFR]
30 ml/min/1.73 m2) were also treated with intravenous
sodium bicarbonate. Only one renal artery lesion was
treated at any given procedural setting. Bilateral lesions
were treated in a staged fashion to minimize the volume
administered and nephrotoxic effects of iodinated contrast
and to avoid the potential for bilateral ischemic renal com-
plications.
Femoral sheath access was employed for all procedures
in this report and intravenous heparin administered (50 to
100 U/kg per surgeon preference) once access was se-
cured. Iodixanol (Visipaque, AmershamHealth, Princeton,
NJ) was used as the intra-arterial contrast medium for all
procedures. Selective renal artery cannulation was accom-
plished using a minimal contact technique of ostial engage-
ment with an angled guiding catheter telescoped through a
10-cm 6 French sheath. Guidewire crossing of the lesion
was performed using a commercially available temporary
balloon occlusion and aspiration 0.014-inch DEP guide-
wire system (Guardwire, Medtronic, Minneapolis, Minn).
The distal occlusion balloon was inflated in the distal main
renal artery immediately after crossing the lesion and occlu-
sion confirmed by hand injection of contrast. RA-PTASwas
then performed using angioplasty balloons with or without
balloon mounted stents (Genesis, Cordis, Miami FL; or
Racer, Medtronic, Minneapolis Minn) of operator choice
sized to match the distal, normal appearing renal artery.
Predilation angioplasty was performed at the discretion of
the operating surgeon with the balloon occlusion device in
place and inflated. Stents were positioned to extend 1 to 2
mm into the aortic lumen while completely covering the
lesion. Following angioplasty  stent deployment, thestatic column of blood proximal to the temporary occlusion
balloon was evacuated using a rapid exchange aspiration
catheter (Export catheter, Medtronic, Minneapolis Minn).
Sixty ml of blood was aspirated and the aspiration catheter
was then used to inject at least 20 ml of heparinized 0.9%
saline to flush any residual debris from the renal artery. The
temporary occlusion balloon was then deflated and com-
pletion renal arteriography was performed. Routine fol-
low-up included clinic visits at 4 weeks, 6 months, 1 year
and, then, yearly with repeat measurement of blood pres-
sure and serum creatinine.
Specimen collection and analysis. Specimen analysis
and processing was conducted at the University of Califor-
nia San Francisco. The initial 5 ml of aspirated blood was
transferred to tubes containing 0.109 molar buffered so-
dium citrate (BD Vacutainer, Becton Dickinson and Com-
pany, Franklin Lakes, NJ) and stored at 4°C until particle
analysis was performed.
For particle analysis, the samples were diluted in an
equal volume of 0.9% saline and passed through a 20 m
filter. Fragments retained on the 20 m filter were then
resuspended in sterile saline and passed through a 60 m
filter. Particles 20 to 60 m in diameter (contained in the
effluent after passage through the 60 m filter) were sized
and counted using a Coulter Counter (BeckmanMultisizer
3, Beckman Coulter Inc, Fullerton Calif). Particles 60
m in diameter (retained on the 60 m filter) were re-
moved, resuspended, counted, and categorized in 100 m
increments under a light microscope at 100x magnification
against a 100 mbackground grid. In order to estimate the
relative contribution of contaminant debris to specimen
particle counts, “sham” particle counts were performed on
sterile saline passed through filters and resuspended in a
manner identical to the handling of specimens. Due to the
size-specific methods of particle number and size determi-
nation, total counts were grouped into size categories of 20
to 60 m and60 m, reflecting the respective thresholds
for use of Coulter Counter vs light microscopy methods for
counting and sizing.
Renal function was evaluated using the abbreviated
modification of diet in renal disease formula for eGFR
calculated from pre- and postoperative serum creatinines:22
eGFR/1.73 m2  186  (Serum Creatinine)1.154 
(Age)0.203 (0.742 if female) (1.210 if African Amer-
ican).
Post revascularization renal function was assessed at 4-
to 8-week follow-up to allow for the effects of perioperative
volume expansion and contrast administration to resolve.
This follow-up time point was chosen due to its coinci-
dence with routinely scheduled follow-up employed by our
group. Renal function response was categorized on a per-
procedure basis as improved or worsened if a 20% in-
crease or decrease in eGFR was observed, respectively.
Those not meeting these criteria were defined as un-
changed.
Blood pressure response was assessed using the highest
measured brachial blood pressure pre- and postoperatively
taken in a sitting position. Blood pressure response was
ck.:
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follows: cured – diastolic blood pressure (DBP) less than 90
mm Hg and systolic blood pressure (SBP) less than 140
mm Hg off all antihypertensive medications; improved –
DBP90 mmHg and/or SBP140 mmHg on the same
or reduced number ofmedications or a reduction inDBP of
at least 15 mm Hg on the same or a reduced number of
medications; failed – no change or inability to meet the
criteria for cure or improvement.
Statistical methods. Descriptive statistics are re-
ported as mean  standard deviation for continuous fac-
tors, and counts and percents for categorical factors. Asso-
ciations between clinical factors and captured debris were
examined using t tests for dichotomous factors and univar-
iate regression analyses for continuous factors. Log trans-
formations of total embolic debris counts 20 to 60 m and
60 m were analyzed to stabilize variances of those
outcomes. Renal function, blood pressure, and antihyper-
tensive agent outcomes following RA-PTAS were exam-
ined using paired t tests. Statistical significance was assessed
at the 0.05 alpha-level. Log transformations of captured
debris counts (20 to 60 m and 60 m), and clinical or
operative predictors of blood pressure response and eGFR
response to RA-PTAS were examined using multiple linear
regression models. For each outcome, a “best” model was
selected using a forward stepwise selection procedure
where the most significant candidate variables with
Table I. Descriptive statistics for patients undergoing RA-
n (%)
Demographics
Age (years)
Caucasian race 21 (82)
Female gender 17 (63)
Preoperative medical data*
SBP (mm Hg)
DBP (mm Hg)
Antihypertensive agents
Serum creatinine (mg/dL)
eGFR (mL min/1.73m2)
Preoperative renal insufficiency 20 (74)
Weight (kg)
Coronary artery disease 8 (30)
Diabetes mellitus 7 (26)
COPD 2 (8)
Tobacco use
Former 13 (48)
Current 4 (15)
Hyperlipidemia 17 (63)
Stroke/TIA 11 (42)
Complicated hypertension 3 (11)
Statin use 9 (33)
Fibrate use 3 (11)
Aspirin use 17 (63)
Clopidogrel use 7 (26)
Aspirin and clopidogrel use 5 (18)
RA-PTAS, renal artery angioplasty and stenting; SBP, systolic blood pres
COPD, chronic obstructive pulmonary disease; TIA, transient ischemic atta
*eGFR 60 mg/mL/1.73m2.P-value .15 were entered one-by-one and retained if theyremained significant at the .10 level after entry. Residuals
for each model were examined after variable selection to
evaluate fit and look for influential observations. All statis-
tical analyses were performed using SAS software, version 9
(SAS Institute Inc, Cary, NC).
RESULTS
Study group. Summary demographic and preopera-
tive clinical data are displayed in Table I. Twenty-eight
RA-PTAS procedures were performed with DEP in 17
female and 10 male patients with a mean age of 72.4 8.6
years. Mean preoperative eGFR and creatinine were 48.9
17.9 mL/min/1.73mL2 and 1.49 0.55 mg/dL, respec-
tively. No patient was dialysis-dependent. All patients were
hypertensive (mean systolic and diastolic blood pressures
were 164.1  21.3 and 81.3  9.0 mm Hg, respectively)
with a mean antihypertensive agent usage of 3.4  1.3.
Procedural data. The 28 RA-PTAS procedures per-
formed during the study period included 26 stent proce-
dures and two primary angioplasty procedures (both for
restenosis). Procedural data are summarized in Table II.
Treated were 25 primary atherosclerotic lesions and four
re-stenotic lesions (three from prior RA-PTAS and one
from prior renal artery endarterectomy). Twenty-six pa-
tients were treated for unilateral disease and one for bilat-
eral disease in a staged fashion. All treated patients had two
kidneys. Mean preoperative renal artery stenosis was 70 
S (N  27)
Mean  SD Minimum Maximum
72.4  8.6 58 88
164  21 124 221
81  9 64 96
3.4  1.3 1 6
1.5  0.6 0.7 3.0
48.9  17.9 15.7 88.6
77.2  17.2 45.9 114.0
BP, diastolic blood pressure; eGFR, estimated glomerular filtration rate;PTA
sure; D12%.Mean balloon occlusion time was 15.7 4.3minutes,
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plete in 26/28 procedures (93%). Lack of complete bal-
loon occlusion was due to an early renal segmental arterial
branch that remained perfused in one patient and a post-
stenotic dilatation in the second patient resulting in
incomplete occlusion with full device inflation. DEP was
attempted and abandoned in a single patient with post-
stenotic renal artery ectasia which did not allow meaningful
balloon occlusion due to size mismatch; this patient there-
fore did not undergo specimen collection and was not
included in analysis. No complications related to RA-PTAS
with DEP were observed. Clinical follow-up occurred at a
mean of 48 days postintervention.
Renal function response at 4 to 8 weeks. Renal
function responses are summarized in Table III. Both pre-
and postoperative laboratory data for determination of
renal functional response at 4 to 8 weeks were available for
22/27 patients. Mean change in creatinine and eGFR were
0.14  0.24 mg/dL and 5.8  8.9 mL/min/1.73mL2,
respectively; both were statistically significant. Renal func-
tion response was defined as improved in eight patients
(36%), unchanged in 14 patients (64%), and worsened in
none. Pre- vs postoperative eGFRs in the two patients with
incomplete renal artery balloon occlusion were 39.2 vs 31.3
Table II. Descriptive statistics for renal angioplasty or sten
n (%)
Preoperative stenosis (%)
Renal artery diameter (mm)
Stent diameter (mm) (N  25)
Renal stent/artery diameter ratio (%) (N  25)
Stent placed 26 (93
Stent type (N  26)
Genesis 24 (93
Racer 2 (8)
Predilation prior to stent placement (N  25) 5 (20
Complete balloon occlusion achieved 26 (93
Balloon occlusion time (minutes) (N  18)
Contrast volume (mL)
N  28 procedures unless otherwise noted.
Table III. Renal function and blood pressure responses fo
embolic protection
Preoperative
Renal function
Serum creatinine (mg/dL) 1.6  0.6
eGFR (mL/min/1.73m2) 47.1  16.7
Blood pressure (mm Hg)
Systolic 163  21
Diastolic 81  9
Antihypertensive agents* 3.2  1.2
eGFR, Estimated glomerular filtration rate.
Descriptive statistics are reported as mean  standard deviation.
N  22 for all parameters except:
*N  24.and 27.2 vs 42.1 mL/min/1.73mL2, respectively.Blood pressure response at 4 to 8 weeks. Pre- and
postoperative blood pressure and antihypertensive medica-
tion use are summarized in Table III. Data on blood
pressure response were available for 25/27 patients. Statis-
tically significant decreases in SBP, DBP, and number of
antihypertensive agents were observed. At 4- to 8-week
follow-up, blood pressure response was defined as cured in
zero patients, improved in 12 (48%), and failed in 13 (52%).
Embolic particle analysis. Particle size and count
data are summarized in the figure (Fig). Mean total number
of embolic particles counted per procedure was 2033 
1553 for particles 20 to 60 m and 265 132 for particles
60 m. Mean “sham” total particle count was 26.5 
10.4 (range 11 to 46). For captured particle counts 20 to
60 m, significant multivariate associations were observed
with African American race (P  .002), predilation (P 
.005), and stent diameter (P .0001). Preoperative aspirin
use was associated with significantly lower captured particle
counts (P  .016). For captured particles 60 m, a
significant multivariate association was observed between
the ratio of renal artery stent diameter to renal artery
diameter (P  .009) and increasing particle counts.
Mean particle counts for patients treated for restenotic
lesions (N  4) were: 4121  2682 (60 microns) and
procedures performed with distal embolic protection
Mean  SD Minimum Maximum
70  12 60 95
5.1  1.1 3.6 8.2
5.3  0.6 4.0 6.0
95  17 72 137
15.7  4.3 8.0 22.0
60.3  31.3 20 130
ing percutaneous renal revascularization with distal
Postoperative Difference P value
1.4  0.6 0.1  0.2 .013
52.9  17.9 5.8  8.8 .006
141  23 22  30 .001
72  11 8  11 .001
2.9  1.2 0.3  0.4 .011ting
)
)
)
)llow298  132 (60 microns). Additional multiple regression
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not significantly affect predictors of embolic counts or renal
functional outcomes.
Associations between captured particle counts and renal
function/blood pressure responses: In multivariate models, a
significant association was observed between increasing cap-
tured particle counts 60 m and decreasing postoperative
eGFR (P  .015). Other significant predictors of postopera-
tive eGFR included preoperative eGFR (P .001) and aspirin
use (P  .006). No significant associations between blood
pressure response (systolic or diastolic) and captured embolic
particle counts were observed.
DISCUSSION
This report describes embolic debris collected from 28
RA-PTAS procedures using DEP. On average, over 2000
particles were captured per procedure. Significant associations
were observed between procedural/anatomic factors and the
amount of captured debris including renal stent size, preop-
erative aspirin use, predilation, and the ratio of renal artery
stent diameter to artery diameter. Increasing captured particle
counts60 m demonstrated a significant and independent
association with impaired renal function response post revas-
cularization.
Procedure-related atheroembolismhas beenpostulated as
a factor capable of limiting the clinical results achieved with
RA-PTAS. Previously published ex-vivo16,24,25 and clinical
data14,17-20 have demonstrated debris liberation with a
variety of angioplasty/stenting models and methods of
Fig. Particle counts by size from renal artery aspirates following
RA-PTASwith distal embolic protection. Lower and upper sides of
the “boxes” are drawn at the 25th and 75th percentiles, respec-
tively, with a horizontal line at the medians and “whiskers” extend-
ing the 10th and 90th percentiles.perioperative circulatory/end-organ monitoring.26-28 Ex-vivo data16 have demonstrated the liberation of large num-
bers of particles with an inverse relationship between parti-
cle size and number with large numbers of released particles
larger than the afferent arterioles (30 to 50 m) of the
kidney. These data have also suggested that atheroemboli-
zation occurs with equal frequency during each step of a
typical RA-PTAS procedure. These ex-vivo findings have
been corroborated, in some areas, and expanded upon by
data from a variety of clinical intraoperative monitoring and
postoperative imaging studies.26-28
The data presented in this report are consistent with the
ex-vivo observations referenced above. A large number of
particles were captured and quantified in blood samples re-
trieved from the renal artery during RA-PTAS with a tempo-
rary distal balloon occlusion and aspiration device. Previously
noted relationships between particle size and number were
again observed, with consistent liberation of particles large
enough to occlude the microvasculature of the nephron.
Protecting the renal circulation from these embolic parti-
cles released during RA-PTAS would seem to be an obvious
goal as a logical extension of these data. The potential need for
such protectionwas anticipated by themedical device industry
prior to the publication of related data. A variety of embolic
protection devices have been commercially available for sev-
eral years with FDA-approved indications for use in coronary
saphenous vein grafts and carotid artery stenting. Use of these
devices has been extended, “off-label”, to RA-PTAS, and
reports detailing their use have been published by several
groups, including our own.14,17-20 These authors have re-
ported positive results in comparison with historical controls
in terms of improved renal function and/or protection from
renal function deterioration. These reports have also provided
limited descriptions of collected debris, reporting a 44% to
100% capture of visible debris with collected particle numbers
in the hundreds to thousands. The data in this report provide
further corroboration of the previously reported findings and
expand on existing knowledge regarding the quantity, size,
and distribution of liberated embolic debris. While grossly
visible debris was visible among a subset of patients, proce-
dure-related liberation of microscopically visible debris oc-
curred among all patients undergoingRA-PTAS.A significant
rate of positive renal function response to RA-PTAS with
distal embolic protection was also observed in the current
sample and no short-term renal function deterioration was
noted.
In an exploratory analysis of associations with captured
debris, significant and independent associations were ob-
served between captured particle counts and potential precip-
itants of particle liberation including predilation, renal artery
stent diameter, and the ratio of renal stent to arterial diameter.
Furthermore, in multiple linear regression models, a signifi-
cant inverse association was observed between the quantity of
collected particles 60 m in diameter and the subsequent
observed change in eGFR post RA-PTAS. Several explana-
tions for these associations exist. The positive associationswith
particle counts 20 to 60mfor renal artery stent diameter and
predilation may represent associations with plaque volume.
The association with predilation may also be indicative of
JOURNAL OF VASCULAR SURGERY
July 200760 Edwards et alparticle liberation during an initial device passage and inflation
in high-grade lesions. Oversizing of the stent relative to the
distal renal arterymay represent another potential explanation
for the association with renal artery stent diameter. This argu-
ment is strengthened by the observation of a strong associa-
tion between stent oversizing (relative to distal arterial diam-
eter) and captured particle counts of debris60 m.
Numerous potential explanations also exist with regard to
the observed inverse association between captured debris
counts and eGFR response. One potential explanation relates
to lesion characteristics; a subset of stenotic lesions may be
qualitatively unstable, or “embolically prone”, and liberate
relatively greater amounts of debris during manipulation. As
such, these lesions may have released significant quantities of
debris during selective angiography and guidewire passage
prior to occlusion of the renal artery using DEP, negatively
impacting subsequent renal function responses. An extension
of this hypothesis would be that these “embolically prone”
lesions continue to shed debris through stent interstices fol-
lowing removal of theDEPdevice, providing a potential nidus
for platelet aggregation and limiting early and sustained renal
function response. These hypotheses are compatible with the
observed association between preoperative aspirin use and
eGFR response. A third potential explanation is that DEPwas
not effective in preventing debris passage and renal function
damage. Our group favors a combination of the “embolically
prone” lesion hypotheses. The lack of observed associations
with other potential precipitants of embolization, such as
lesion length and clopidogrel non-use, could be secondary to
the limited material analyzed or the small sample size.
After controlling for preoperative eGFR, preoperative as-
pirin use was a significant predictor of both captured particle
counts of debris 20 to 60 m and improved postoperative
eGFR, while increasing number of captured fragments 60
m in diameter was associated with a significant decrease in
eGFR. Interestingly, smaller particles (20 to 60m)were not
predictive of postoperative eGFR reduction in our analyses.
Potential explanations exist for these differing results accord-
ing to particle size. First, eGFR is an estimate of global renal
function andmay not be a sensitive enoughmeasure to reflect
minor reductions in single kidney function resulting from
small particle embolization. Second, it is likely that particles
categorized by size criteria and method of quantification may
also differ in their composition (eg, cholesterol fragments,
platelet aggregates and/or thrombus) and resultant end-or-
gan effect following embolization. Finally, particles below a
threshold size may have little or no effect on renal function
following embolization. We suspect that a combination of
these factors explain the observed associations and that further
investigation, including qualitative particle analysis, is war-
ranted.
Captured particle counts in this study were in excess of
those from previous reports using the Guardwire protec-
tion device in the carotid circulation.29,30 This difference in
mean counts may be due to intrinsic differences in anatomic
and/or plaque characteristics between these two arterial
locations. Alternatively, some or all of this difference may
be related to the broader size range of particles counted;our analysis of particles down to a lower size minimum
generated counts that were highest at the smaller end of the
size range. Prior comparisons between balloon vs filter
protection devices have suggested that the balloon devices
are superior in capturing small particles,30 and we continue
to favor such devices at our institution for embolic protec-
tion in the renal system.
If the observed association between captured particles and
renal function response is indeed valid, these data have signif-
icant implications regarding the clinical and operative man-
agement of patients with renal artery stenosis. The rationale
for DEP during RA-PTAS would be further supported with
the goal of optimizing renal function response, especially in
light of previously published data indicating that renal func-
tion response following RA-PTAS is a key determinant of
subsequent morbidity and mortality.11-13 Furthermore, there
would be technical and device specific implications. If embolic
particle liberation is indeed a key event occurring at multiple
successive steps of the procedure, then technical performance
of RA-PTAS must be performed with minimal, gentle lesion
manipulation prior to DEP device deployment. DEP devices
may also require further device-specific refinement to ensure
capture of the correct particle size distribution, to minimize
particle liberation during device passage, and to potentially
eliminate the need for lesion crossing altogether. Finally,
preoperative aspirin use and avoidance of stent oversizing
appeared to be important clinical factors that reduced cap-
tured debris and, by extension, could improve renal functional
outcomes.
While this study provides intriguing data regarding the
liberation of atheroembolic debris during RA-PTAS, numer-
ous limitations exist that deserve comment. First, this report
details an inherently incomplete analysis of liberated debris
due to unavoidable limitations in debris capture. It is likely
that there was considerable loss of debris into the adjacent
aortic blood flow during the procedure as well as potentially
incomplete evacuation through the aspiration catheter limit-
ing the debris available for analysis. Furthermore, only five of
the 60 mL of blood routinely aspirated were analyzed due to
cost and resource constraints. Additionally, this investigation
reports data from a modest sample of 28 RA-PTAS proce-
dures with DEP, limiting inferential power. During aspirate
collection, the particulate material was clearly mobile and
easily aspirated. We believe that this material represents liber-
ated embolic debris, but cannot be certain that the particles
adherent to the luminal surface were not aspirated due to the
negative pressure or possibly liberated by the aspiration cath-
eter rather than during angioplasty and/or stenting. Our use
of saline instead of peripheral blood samples to generate sham
particle counts may have resulted in underestimation of the
contribution of nonembolic blood components to overall
counts. We intend to analyze peripheral blood samples in
addition to saline in future work to determine whether a
change in method is warranted. Renal function response was
measured using a widely accepted GFR estimating equation
based on serum creatinine values and demographics. As pre-
viouslymentioned, this eGFRequation has not been validated
in individuals with RVD and serum creatinine is a relatively
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especially true in individuals with normal renal function, a
group which was significantly represented in this sample.
Finally, qualitative analysis of the liberated debris was not
performed due to the small amounts of material collected;
such analysis might provide further insight into the nature of
procedure-related atheroembolism.
These limitations notwithstanding, this investigation pro-
vides new data regarding the occurrence of embolization
during RA-PTAS and its potential limiting effects on renal
function outcome. Further investigation is required to more
completely define these associations as well as the appropriate
role for DEP devices in the conduct of RA-PTAS.
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